IBD Insights from United European Gastroenterology Week 2015: A faculty roundtable discussion

Program overview

This IBD Dialog will discuss some of the key highlights and insights from United European Gastroenterology Week (UEGW) 2015, held in Barcelona, Spain. This IBD Dialog, in the format of a Faculty Roundtable discussion, will offer a clinically focused update on some of the important information presented during UEGW, as selected by our faculty. The activity will provide you with an insight into some of the key clinical data allowing you to implement new understanding into your own practice

Target audience

This activity has been designed to meet the educational needs of gastroenterologists and registered nurses involved in the care of patients with inflammatory bowel disease (IBD).

Release date: December 1, 2015
Expiry date: December 1, 2016

Learning objectives

After completing this activity, the participant should be better able to:

  • Summarize data related to Crohn's disease (CD) and ulcerative colitis (UC) presented at United European Gastroenterology Week 2015
  • Consider how the data presented may affect clinical practice
  • Evaluate the new data on emerging therapies for IBD
  • Provide appropriate care and counsel for patients and their families.


Jean-Frédéric Colombel, MD (Course Director)
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY


Flemming Bendtsen, MD
Professor and Chief Physician
Department of Gastroenterology
University of Copenhagen
Hvidovre Hospital


Marco Daperno, MD
Consultant Gastroenterologist
Gastroenterology Unit
Mauriziano Hospital
Turin, Italy


Marco Daperno graduated in medicine at Torino University in 1998, and became a gastroenterologist in 2002 at the same University. Since 2007 he has been a gastroenterologist consultant in the Gastroenterology Unit of Mauriziano Hospital in Torino.

From 2002–2003, Dr. Daperno spent a year in a clinical research fellowship at Prof. Rutgeerts' Gastroenterology Unit at Leuven University Hospital in Belgium, and from 2003–2004 at Prof. Jewell's Gastroenterology Unit and Laboratories at Oxford University in the UK.

He currently works in clinical management of inflammatory bowel disease (IBD), with special interest in endoscopy and endoscopic scores, and contributed to the development in this field by producing a mobile application for IBD clinimetry, which has had >1,500 downloads worldwide (IGIBD Scores, http://www.igibdscores.it/en/).

Dr. Daperno has been a member of ECCO since 2002, and of the Italian Group for IBD (IG-IBD) since its birth. He is an author of 49 peer reviewed papers in international journals, with H-Index of 25.

Close Biography

James Lindsay, PhD, FRCP
Consultant Gastroenterologist
Bart's Health NHS Trust
Reader in Inflammatory Bowel Disease
Centre for Immunobiology
Blizard Institute
Queen Mary University of London
London, United Kingdom


Syllabus disclosure statement

Disclosure of conflicts of interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Reported Financial Relationship

Jean-Frédéric Colombel

Consulting fees: Abbvie, Amgen, Celegene, Genentech, Janssen and Janssen, Merck Sharp Dohme, Nestle, Pfizer, Protagonist Therapies, Receptos, Second Genome, Takeda, Tigenix, Vertex

Fees for non-CME/CE services: Abbvie, Ferring, Shire, Takeda

Ownership interest: Intestinal Biotech Development

Flemming Bendtsen

Consulting fees: : Intercept Pharmaceuticals, Ono, Takeda

Marco Daperno

Consulting fees: Abbvie, Hospira, MSD, Mundifarma, Quintiles, Robarts, SOFAR, Takeda

James Lindsay

Consulting fees: Abbvie, MSD, NAPP, Pfizer, Takeda

Fees for non-CME/CE services: Abbvie, Actavis, Ferring, MSD, NAPP, Shire, Takeda, Warner Chilcott

Research: Takeda

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following SCI planners and managers, Ian Morgan, MSc, and Elena Urso, BSc, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity or any amount during the past 12 months.


Physician continuing education

Accreditation statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Strategic Consultants International. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing continuing education

Credit designation

This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Estimated time to complete activity: 90 minutes

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of participation and request for credit

There are no fees for participating and receiving CME/CE credit for this activity. To successfully earn credit, participants must complete the activity online during the valid credit period. Follow these steps to earn CME/CE credit:

  1. Read the target audience, learning objectives, and author disclosures
  2. View the educational content online
  3. Upon completion of the activity, complete the online posttest and Activity Evaluation to provide feedback for future programming.

Upon successful completion of the posttest, with a score of 75% or better, and the online Evaluation form, you will have immediate access to a certificate of attendance to print or save for your files.

If you have any questions regarding the CME/CE certification for this activity, please contact Postgraduate Institute for Medicine at: information@pimed.com or (303) 799-1930.

Media: Internet


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Jointly provided by the Postgraduate Institute for Medicine and
Strategic Consultants International
PIM Logo  
This activity is supported by an independent educational grant from
Takeda Pharmaceuticals International, Inc., US Region,
UCB, Inc., and Prometheus.